Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 15/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 8/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.38 |
| ▸ | IARS1 | P41252 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28044917 | 1.00 | DPP4 (0.42) | DPP4DPP8DPP9SLC7A5DPP7 | |
| SCHEMBL5161688 | 0.94 | DPP4 (0.46) | DPP4DPP8DPP9DPP7IARS1 | |
| SCHEMBL3930248 | 0.94 | DPP4 (0.46) | DPP4DPP8DPP9DPP7IARS1 | |
| Threonine SCHEMBL4616599 | 0.88 | SLC7A5 (0.44) | DPP4DPP8DPP9SLC7A5DPP7 | |
| SCHEMBL1537392 | 0.88 | DPP4 (0.42) | DPP4DPP8DPP9DPP7IARS1 | |
| SCHEMBL1537362 | 0.88 | DPP4 (0.42) | DPP4DPP8DPP9DPP7IARS1 | |
| SCHEMBL2052320 | 0.86 | DPP4 (0.41) | DPP4DPP8DPP9DPP7IARS1 | |
| SCHEMBL288204 | 0.84 | SLC7A5 (0.52) | DPP4DPP8DPP9SLC7A5DPP7 | |
| SCHEMBL10530419 | 0.84 | SLC7A5 (0.52) | DPP4DPP8DPP9SLC7A5DPP7 | |
| SCHEMBL27932393 | 0.84 | SLC7A5 (0.52) | DPP4DPP8DPP9SLC7A5DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626156-B2 | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs | Han, Jie (US) | 2020-04-21 | — | — | US | claimed |
| US-20180296522-A1 | ENHANCED EXPRESSION OF mTOR AND INHIBITED EXPRESSION OF MYOSTATIN IN SKELETAL MUSCLE CELLS | IN INGREDIENTS, INC. (US) | 2018-10-18 | — | — | US | claimed |
| WO-2016073843-A2 | ENHANCED EXPRESSION OF MTOR AND INHIBITED EXPRESSION OF MYOSTATIN IN SKELETAL MUSCLE CELLS | IN INGREDIENTS, INC. (US) | 2016-05-12 | — | — | WO | claimed |
| EP-2366786-A2 | Cytokine receptor modulators and uses thereof | VALORISATION HSJ, Société en Commandite (CA) | 2011-09-21 | — | — | EP | claimed |
| EP-2245148-A1 | CELLULASE VARIANTS WITH REDUCED INHIBITION BY GLUCOSE | Iogen Energy Corporation (CA) | 2010-11-03 | — | — | EP | claimed |
| US-20090186381-A1 | CELLULASE VARIANTS WITH REDUCED INHIBITION BY GLUCOSE | IOGEN ENERGY CORPORATION (CA) | 2009-07-23 | — | — | US | claimed |
| WO-2009089630-A1 | CELLULASE VARIANTS WITH REDUCED INHIBITION BY GLUCOSE | IOGEN ENERGY CORPORATION (CA) | 2009-07-23 | — | — | WO | claimed |
| EP-1885855-A4 | CYTOKINE RECEPTOR MODULATORS AND USES THEREOF | VALORISATION HSJ SOC EN COMMAN (CA) | 2009-03-04 | — | — | EP | claimed |
| US-20090048161-A1 | Cytokine receptor modulators and uses thereof | VALORISATION HSJ, SOCIETE EN COMMANDITE (CA) | 2009-02-19 | — | — | US | claimed |
| US-20090018196-A1 | FOOD COMPOSITION COMPRISING AMINO ACIDS | INNOVAFOOD AB (SE) | 2009-01-15 | — | — | US | claimed |
| EP-1414431-B1 | AMINO-ACID-BASED therapeutic COMPOSITIONS, FOR THE HEALING AND/OR MENDING OF WOUNDS AND LESIONS, IN PARTICULAR IN THE OPHTHALMIC FIELD | SOLARTIUM ENTPR LTD (IE) | 2008-07-16 | — | — | EP | claimed |
| EP-1885855-A2 | CYTOKINE RECEPTOR MODULATORS AND USES THEREOF | VALORISATION HSJ, Société en Commandite (CA) | 2008-02-13 | — | — | EP | claimed |
| WO-2007004060-A2 | CYTOKINE RECEPTOR MODULATORS AND USES THEREOF | VALORISATION HSJ, SOCIETE EN COMMANDITE (CA) | 2007-01-11 | — | — | WO | claimed |
| US-6342243-B1 | ORALLY ADMINISTERING AN AMINO ACID AND/OR A PEPTIDE TO A NEONATAL RUMINANT FOR A PERIOD OF FROM A DAY AFTER SAID RUMINANT'S BIRTH UNTIL THE FUNCTION OF THE RUMEN DEVELOPS. | AJINOMOTO CO., INC. (JP) | 2002-01-29 | — | — | US | claimed |
| CN-113122521-B | Polypeptides having lipase activity and uses thereof | 丰益国际有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117165545-A | Alpha-isopropyl malate synthase mutant, recombinant microorganism and application thereof | 胡丹 | 2023-12-05 | — | — | CN | disclosed |
| CN-117137977-A | Preparation method of lactation-promoting traditional Chinese medicine composition for sows | 北京中农劲腾生物制药股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-4508823-A | GENETIC ENGINEERING-CHROMOSOMAL DNA SPLITTING WITH ENZYME, THEN JOINING TO HGIVE PLASMID/- | MICROLIFE TECHNICS, INC. (US) | 1985-04-02 | — | — | US | disclosed |
| US-4391907-A | GENETIC ENGINEERING | AJINOMOTO COMPANY INCORPORATED (JP) | 1983-07-05 | — | — | US | disclosed |
| EP-0030727-A2 | Method for producing L-valine by fermentation and method for producing a new microorganism of the genus Escherichia | AJINOMOTO CO., INC. (JP) | 1981-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626156-B2 | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs | NOS2, EGLN2, HPGD | DPP4 1564/4885DPP8 1691/4885DPP9 1143/4885 |
| US-20180296522-A1 | ENHANCED EXPRESSION OF mTOR AND INHIBITED EXPRESSION OF MYOSTATIN IN SKELETAL MUSCLE CELLS | MSTN, MTPN, MTOR | DPP4 3235/4885DPP8 1545/4885DPP9 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.